Aster DM Healthcare Limited — quarter and year ended 31 March 2026
| Particulars | Quarter ended (Unaudited) | Year ended (Audited) |
|---|---|---|
| 31 March 2026 (refer Note 8) | 31 March 2026 | |
| 1 Income | ||
| Revenue from operations | 655.10 | 2,615.70 |
| Other income | 40.55 | 155.03 |
| Total income | 695.65 | 2,770.73 |
| 2 Expenses | ||
| Purchase of medicines and medical consumables | 122.14 | 530.68 |
| Changes in inventories | 8.15 | 8.49 |
| Professional fees to consultant doctors | 149.99 | 579.85 |
| Laboratory outsourcing charges | 18.98 | 78.55 |
| Employee benefits expense | 103.94 | 403.45 |
| Finance costs | 20.98 | 87.27 |
| Depreciation and amortisation expenses | 37.57 | 154.02 |
| Other expenses | 113.53 | 464.30 |
| Total expenses | 575.28 | 2,306.61 |
| 3 Profit before exceptional items and tax (1-2) | 120.37 | 464.12 |
| 4 Exceptional items (refer Notes 6) | (77.73) | (89.92) |
| 5 Profit before tax (3+4) | 42.64 | 374.20 |
| 6 Tax expenses | ||
| – Current tax | 19.93 | 124.37 |
| – Deferred tax | (4.75) | (17.99) |
| Total tax expense | 15.18 | 106.38 |
| 7 Profit for the period / year (5-6) | 27.46 | 267.82 |
| 8 Other comprehensive income/(loss) for the period / year | ||
| Items that will not be reclassified subsequently to profit or loss | ||
| – Remeasurement of net defined benefit liability | 1.18 | (0.21) |
| – Income tax relating to items that will not be reclassified to profit or loss | (0.30) | 0.05 |
| Other comprehensive income/(loss), net of taxes | 0.88 | (0.16) |
| 9 Total comprehensive income (7+8) | 28.34 | 267.66 |
| 10 Paid-up equity share capital (Face value of INR 10 each) | 518.13 | 518.13 |
| 11 Other equity | 3,848.09 | |
| 12 Earnings per share (Face value of INR 10 each) | ||
| – Basic (in INR) | 0.53 | 5.20 |
| – Diluted (in INR) | 0.53 | 5.19 |
| Particulars | As at 31 March 2026 | As at 31 March 2025 |
|---|---|---|
| A ASSETS | ||
| 1 Non-current assets | ||
| Property, plant and equipment | 1,051.39 | 1,021.20 |
| Right-of-use assets | 918.91 | 737.99 |
| Capital work-in-progress | 160.08 | 55.41 |
| Other intangible assets | 2.08 | 1.25 |
| Financial assets | ||
| Investments | 2,215.67 | 1,008.96 |
| Loans | 279.59 | 316.12 |
| Other financial assets | 124.88 | 110.13 |
| Income tax assets | 43.93 | 76.41 |
| Other non-current assets | 32.88 | 25.67 |
| Total non-current assets | 4,829.41 | 3,353.14 |
| 2 Current assets | ||
| Inventories | 33.24 | 41.73 |
| Financial assets | ||
| Trade receivables | 178.94 | 138.13 |
| Cash and cash equivalents | 119.44 | 119.84 |
| Bank balances other than cash and cash equivalents above | 1,006.09 | 1,168.87 |
| Other financial assets | 139.29 | 117.97 |
| Other current assets | 33.63 | 25.08 |
| Total current assets | 1,510.63 | 1,611.62 |
| TOTAL ASSETS | 6,340.04 | 4,964.76 |
| B EQUITY AND LIABILITIES | ||
| 1 Equity | ||
| Equity share capital | 518.13 | 499.52 |
| Other equity | 3,848.09 | 2,839.97 |
| Total equity | 4,366.22 | 3,339.49 |
| 2 Liabilities | ||
| 2(a) Non-current liabilities | ||
| Financial liabilities | ||
| Borrowings | 239.94 | 298.46 |
| Lease liabilities | 1,014.11 | 806.10 |
| Deferred tax liabilities (net) | 30.92 | 48.96 |
| Other non-current liabilities | 37.88 | 35.96 |
| Provisions | 19.76 | 14.91 |
| Total non-current liabilities | 1,342.61 | 1,204.39 |
| 2(b) Current liabilities | ||
| Financial liabilities | ||
| Borrowings | 73.74 | 78.92 |
| Lease liabilities | 19.07 | 16.48 |
| Trade payables – Total outstanding dues of micro and small enterprises | 21.66 | 9.52 |
| Trade payables – Total outstanding dues of creditors other than micro and small enterprises | 270.68 | 238.39 |
| Other financial liabilities | 205.52 | 35.28 |
| Other current liabilities | 35.75 | 40.72 |
| Provisions | 4.79 | 1.57 |
| Total current liabilities | 631.21 | 420.88 |
| TOTAL EQUITY AND LIABILITIES | 6,340.04 | 4,964.76 |
| Particulars | For the year ended 31 March 2026 (Audited) | For the year ended 31 March 2025 |
|---|---|---|
| Cash flows from operating activities | ||
| Profit before tax for the year | 374.20 | 6,288.25 |
| Adjustments for non cash and non operating items | ||
| Depreciation and amortisation expenses | 154.02 | 144.52 |
| Finance costs | 87.27 | 85.57 |
| Dividend income on non-current investments | (11.95) | (5,577.90) |
| Profit on sale of investment | – | (381.12) |
| Interest income and other non-operating income | (124.38) | (139.80) |
| Allowances for credit losses on financial assets | 7.96 | 9.68 |
| Equity settled share based payment | 8.31 | 8.42 |
| Impact of lease modification | – | (7.22) |
| Loss on sale of property, plant and equipment (net) | 1.19 | 0.41 |
| Provision for diminution in value of investments | 57.24 | – |
| Intangible assets under development written off | – | 0.15 |
| Operating cash flows before movements in working capital | 553.86 | 430.96 |
| Working capital adjustments | ||
| Changes in trade receivables | (48.77) | (20.26) |
| Changes in inventories | 8.49 | 1.82 |
| Changes in other financial assets | (101.00) | (2.81) |
| Changes in other assets | (14.03) | (0.46) |
| Changes in trade payables | 44.43 | 23.39 |
| Changes in provisions | 8.28 | 2.81 |
| Changes in other financial liabilities | 25.08 | (11.74) |
| Changes in other liabilities | 2.78 | 9.97 |
| Cash generated from operating activities | 479.12 | 433.68 |
| Taxes paid, net of refund received | (91.99) | (66.45) |
| Net cash generated from operating activities (A) | 387.13 | 367.23 |
| Cash flows from investing activities | ||
| Movement in other bank balances and restricted deposits | 164.19 | (1,161.74) |
| Redemption of /(Investment in) subsidiaries and associates (net) | (179.21) | 1,759.14 |
| (Investments in)/proceeds from sale of mutual funds (net) | – | 8.42 |
| Interest received | 70.36 | 58.06 |
| Dividend received | 11.95 | 5,577.90 |
| Payment to acquire intangible assets | (2.27) | (0.56) |
| Payment to acquire property, plant and equipment (including capital work-in-progress) | (153.84) | (138.31) |
| Proceeds on sale of property, plant and equipment | 1.09 | 1.11 |
| Net cash generated from / (used in) investing activities (B) | (143.59) | 6,023.00 |
| Cash flows from financing activities | ||
| Payment of lease liabilities | (88.78) | (80.41) |
| Finance cost paid | (32.63) | (37.83) |
| Dividend paid | (51.87) | (6,173.59) |
| Proceeds from exercise of share options | 2.50 | 3.09 |
| Long term secured loans availed | 6.46 | 125.02 |
| Long term secured loans repaid | (79.62) | (65.39) |
| Current borrowings (repaid)/availed, net | – | (69.00) |
| Net cash used in financing activities (C) | (243.94) | (6,298.11) |
| Net increase/(decrease) in cash and cash equivalents (A+B+C) | (0.40) | 92.12 |
| Cash and cash equivalents at the beginning of the year | 119.84 | 27.72 |
| Cash and cash equivalents at the end of the year | 119.44 | 119.84 |
| Particulars | For the year ended 31 March 2026 | For the year ended 31 March 2025 |
|---|---|---|
| Cash and cash equivalents comprises of: | ||
| a) Cash on hand | 1.04 | 1.68 |
| b) Balance with banks | 118.37 | 118.11 |
| c) Cash /Cheques- in transit | 0.03 | 0.05 |
| Total | 119.44 | 119.84 |
| Particulars | As at 01 April 2025 | Cash inflows | Cash outflows | Additions/Modifications | Non cash changes | Finance costs | As at 31 March 2026 |
|---|---|---|---|---|---|---|---|
| Borrowings (Current and Non-current) including interest | 377.66 | 6.46 | (112.25) | – | 9.06 | 32.91 | 313.84 |
| Lease liabilities | 822.58 | – | (88.78) | 228.22 | 16.80 | 54.36 | 1,033.18 |
| Total | 1,200.24 | 6.46 | (201.03) | 228.22 | 25.86 | 87.27 | 1,347.02 |
| Particulars | As at 01 April 2024 | Cash inflows | Cash outflows | Additions/Modifications | Non cash changes | Finance costs | As at 31 March 2025 |
|---|---|---|---|---|---|---|---|
| Borrowings (Current and Non-current) including interest | 387.16 | 125.02 | (172.22) | – | 1.93 | 35.77 | 377.66 |
| Lease liabilities | 454.69 | – | (80.41) | 384.40 | 14.10 | 49.80 | 822.58 |
| Total | 841.85 | 125.02 | (252.63) | 384.40 | 16.03 | 85.57 | 1,200.24 |
| Particulars | Quarter ended | Year ended | |||
|---|---|---|---|---|---|
| 31 March 2026 | 31 December 2025 | 31 March 2025 | 31 March 2026 | 31 March 2025 | |
| (Unaudited) | (Unaudited) | (Unaudited) | (Audited) | (Audited) | |
| 1. Continuing operations – Income | |||||
| Revenue from operations | 1,182.38 | 1,185.76 | 1,000.34 | 4,643.22 | 4,138.46 |
| Other income | 36.20 | 27.97 | 31.28 | 125.60 | 148.23 |
| Total income | 1,218.58 | 1,213.73 | 1,031.62 | 4,768.82 | 4,286.69 |
| 2. Expenses | |||||
| Purchase of medicines and medical consumables | 258.97 | 270.44 | 218.17 | 1,047.61 | 920.16 |
| Changes in inventories | 4.19 | (2.96) | 7.06 | 1.18 | 18.17 |
| Professional fees to consultant doctors | 264.66 | 270.36 | 229.98 | 1,031.87 | 921.17 |
| Laboratory outsourcing charges | 5.35 | 8.28 | 6.99 | 27.52 | 29.21 |
| Employee benefits expense | 219.99 | 221.37 | 182.96 | 848.09 | 760.39 |
| Finance costs | 29.99 | 31.46 | 32.43 | 122.98 | 123.81 |
| Depreciation and amortisation expenses | 67.24 | 67.67 | 63.95 | 264.25 | 248.84 |
| Other expenses | 196.64 | 207.02 | 163.11 | 785.92 | 724.83 |
| Total expenses | 1,047.03 | 1,073.64 | 904.65 | 4,129.42 | 3,746.58 |
| 3. Profit before share of loss of equity accounted investees, exceptional items and tax (1-2) | 171.55 | 140.09 | 126.97 | 639.40 | 540.11 |
| 4. Share of loss of equity accounted investees | (8.53) | (8.75) | (10.01) | (37.00) | (18.91) |
| 5. Exceptional items (Refer Note 5) | 0.33 | (28.29) | (26.42) | (32.71) | (50.14) |
| 6. Profit before tax (3+4+5) | 163.35 | 103.05 | 90.54 | 569.69 | 471.06 |
| 7. Tax expense | |||||
| Current tax | 36.37 | 59.14 | 18.01 | 186.03 | 125.73 |
| Deferred tax | (26.60) |